Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Kurma Partners
Deal Size : $12.8 million
Deal Type : Financing
Ermium Therapeutics Extends Its Initial €6.3 M Funding to €12.3 M
Details : The company is discovering and developing small molecules, orally available, that are aimed at addressing a range of chronic auto-immune diseases, affecting millions of people worldwide, and particularly type I interferon-mediated diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 30, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Kurma Partners
Deal Size : $12.8 million
Deal Type : Financing
Reset All
